AxoGen (NASDAQ:AXGN) Issues Earnings Results

Posted by Scott Davis on Feb 23rd, 2021

AxoGen (NASDAQ:AXGN) released its quarterly earnings results on Sunday. The medical equipment provider reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.08, MarketWatch Earnings reports. AxoGen had a negative net margin of 22.98% and a negative return on equity of 19.83%.

NASDAQ AXGN traded up $0.54 during trading hours on Tuesday, hitting $21.73. The company’s stock had a trading volume of 24,292 shares, compared to its average volume of 249,087. The stock has a fifty day moving average of $19.02 and a 200 day moving average of $14.98. AxoGen has a twelve month low of $7.16 and a twelve month high of $21.76. The firm has a market capitalization of $882.65 million, a P/E ratio of -35.14 and a beta of 0.71. The company has a quick ratio of 6.81, a current ratio of 7.45 and a debt-to-equity ratio of 0.42.

A number of equities analysts have recently issued reports on the stock. SVB Leerink upped their target price on shares of AxoGen from $23.00 to $27.00 and gave the stock an “outperform” rating in a research report on Tuesday. Canaccord Genuity reiterated a “hold” rating and set a $21.00 target price (up from $20.00) on shares of AxoGen in a research report on Tuesday. Finally, Cantor Fitzgerald increased their price objective on shares of AxoGen from $16.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, January 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.75.

In related news, CEO Karen L. Zaderej sold 65,000 shares of the stock in a transaction that occurred on Friday, January 8th. The shares were sold at an average price of $20.00, for a total value of $1,300,000.00. Following the transaction, the chief executive officer now directly owns 609,099 shares in the company, valued at $12,181,980. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 72,932 shares of company stock worth $1,439,869 over the last 90 days. 6.94% of the stock is currently owned by company insiders.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

AxoGen (NASDAQ:AXGN) Issues Earnings Results

Latest News